Nsengi Yumva Ntamabyaliro

Dr. Nsengi Yumva Ntamabyaliro

University of Kinshasa, Kinshasa, Democratic Republic of the Congo
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
LMLeah F. Moriarty
Leah F. Moriarty
MNMandoko Papy Nkoli
Mandoko Papy Nkoli
JLJoris LOSIMBA LIKWELA
Joris LOSIMBA LIKWELA
PMPatrick Mulopo Mitashi
Patrick Mulopo Mitashi
ESEric Mukomena Sompwe
Eric Mukomena Sompwe
MGMESIA KAHUNU GAUTHIER
MESIA KAHUNU GAUTHIER
: Routine assessment of the efficacy of artemisinin-based combination therapies (ACTs) is critical for the early detection of antimalarial resistance. We evaluated the efficacy of ACTs recommended for treatment of uncomplicated malaria in five sites in Democratic Republic of the Congo (DRC): artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP). Children aged 6–59 months with confirmed Plasmodium falciparum malaria were treated with one of the three ACTs and monitored. The primary endpoints were uncorrected and polymerase chain reaction (PCR)-corrected 28-day (AL and ASAQ) or 42-day (DP) cumulative efficacy. Molecular markers of resistance were investigated. Across the sites, uncorrected efficacy estimates ranged from 63% to 88% for AL, 73% to 100% for ASAQ, and 56% to 91% for DP. PCR-corrected efficacy estimates ranged from 86% to 98% for AL, 91% to 100% for ASAQ, and 84% to 100% for DP. No pfk13 mutations previously found to be associated with ACT resistance were observed. Statistically significant associations were found between certain pfmdr1 and pfcrt genotypes and treatment outcome. There is evidence of efficacy below the 90% cutoff recommended by WHO to consider a change in first-line treatment recommendations of two ACTs in one site not far from a monitoring site in Angola that has shown similar reduced efficacy for AL. Confirmation of these findings in future therapeutic efficacy monitoring in DRC is warranted.

15 June 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
GLGaston Tona Lutete
Gaston Tona Lutete
Ghyslain Mombo-NgomaGhyslain Mombo-Ngoma
Ghyslain Mombo-Ngoma
SASerge-Brice Assi
Serge-Brice Assi
JBJude D Bigoga
Jude D Bigoga
FKFelix Koukouikila-Koussounda
Felix Koukouikila-Koussounda
TGthe CANTAM study group
the CANTAM study group
Background: In Phase II/III randomized controlled clinical trials for the treatment of acute uncomplicated malaria, pyronaridine–artesunate demonstrated high efficacy and a safety profile consistent with that of comparators, except that asymptomatic, mainly mild-to-moderate transient increases in liver aminotransferases were reported for some patients. Hepatic safety, tolerability, and effectiveness have not been previously assessed under real-world conditions in Africa. Methods and findings: This single-arm, open-label, cohort event monitoring study was conducted at 6 health centers in Cameroon, Democratic Republic of Congo, Gabon, Ivory Coast, and Republic of Congo between June 2017 and April 2019. The trial protocol as closely as possible resembled real-world clinical practice for the treatment of malaria at the centers. Eligible patients were adults or children of either sex, weighing at least 5 kg, with acute uncomplicated malaria who did not have contraindications for pyronaridine–artesunate treatment as per the summary of product characteristics. Patients received fixed-dose pyronaridine–artesunate once daily for 3 days, dosed by body weight, without regard to food intake. A tablet formulation was used in adults and adolescents and a pediatric granule formulation in children and infants under 20 kg body weight. The primary outcome was the hepatic event incidence, defined as the appearance of the clinical signs and symptoms of hepatotoxicity confirmed by a >2× rise in alanine aminotransferase/aspartate aminotransferase (ALT/AST) versus baseline in patients with baseline ALT/AST >2× the upper limit of normal (ULN). As a secondary outcome, this was assessed in patients with ALT/AST >2× ULN prior to treatment versus a matched cohort of patients with normal baseline ALT/AST. The safety population comprised 7,154 patients, of mean age 13.9 years (standard deviation (SD) 14.6), around half of whom were male (3,569 [49.9%]). Patients experienced 8,560 malaria episodes; 158 occurred in patients with baseline ALT/AST elevations >2×ULN. No protocol-defined hepatic events occurred following pyronaridine–artesunate treatment of malaria patients with or without baseline hepatic dysfunction. Thus, no cohort comparison could be undertaken. Also, as postbaseline clinical chemistry was only performed where clinically indicated, postbaseline ALT/AST levels were not systematically assessed for all patients. Adverse events of any cause occurred in 20.8% (1,490/7,154) of patients, most frequently pyrexia (5.1% [366/7,154]) and vomiting (4.2% [303/7,154]). Adjusting for Plasmodium falciparum reinfection, clinical effectiveness at day 28 was 98.6% ([7,369/7,746] 95% confidence interval (CI) 98.3 to 98.9) in the per-protocol population. There was no indication that comorbidities or malnutrition adversely affected outcomes. The key study limitation was that postbaseline clinical biochemistry was only evaluated when clinically indicated. Conclusions: Pyronaridine–artesunate had good tolerability and effectiveness in a representative African population under conditions similar to everyday clinical practice. These findings support pyronaridine–artesunate as an operationally useful addition to the management of acute uncomplicated malaria. Trial registration: ClinicalTrials.gov NCT03201770.

3 September 2018 in Vaccine
Verified
Journal Article
Closed access
DNDidier Nzolo
Didier Nzolo
ABAline Engo Biongo
Aline Engo Biongo
AKAndrea Kuemmerle
Andrea Kuemmerle
MLMariano Lusakibanza
Mariano Lusakibanza
YLYves Lula
Yves Lula
Jean-Pierre Van GeertruydenJean-Pierre Van Geertruyden
Jean-Pierre Van Geertruyden

Verified
Journal Article
Open access
PDF file
NNNsengi Yumva Ntamabyaliro
Nsengi Yumva Ntamabyaliro
Christian BurriChristian Burri
Christian Burri
YLYves N. Lula
Yves N. Lula
DIDaniel Ishoso
Daniel Ishoso
Aline EngoAline Engo
Aline Engo
GTGaston L. Tona
Gaston L. Tona
(1) Background: The Democratic Republic of the Congo (DRC) is heavily affected by malaria despite availability of effective treatments. Ignorance and unrecommended behaviour toward a suspected malaria case in households may contribute to this problem. (2) Method: In communities of one rural and one urban Health Centres in each of the 11 previous provinces of DRC, all households with a case of malaria in the 15 days prior to the survey were selected. The patient or caregiver (responder) were interviewed. Logistic regression was used to assess predictors of knowledge of recommended antimalarials and adequate behaviour in case of suspected malaria. (3) Results: 1732 households participated; about 62% (1060/1721) of the responders were informed about antimalarials, 70.1% (742/1059) knew the recommended antimalarials and 58.6% (995/1699) resorted to self-medication. Predictors of knowledge of antimalarials were education to secondary school or university, information from media and smaller households. Predictors of good behaviour were Catholic religion and smaller households. Receiving information from Community Health Workers (CHWs) failed to be determinants of knowledge or adequate behaviour. (4) Conclusion: malaria control in DRC is hampered by ignorance and non-adherence to national recommendations. These aspects are influenced by unsuccessful communication, size of households and level of education.

Verified
Journal Article
Open access
PDF file
NNNsengi Yumva Ntamabyaliro
Nsengi Yumva Ntamabyaliro
Christian BurriChristian Burri
Christian Burri
YLYves N. Lula
Yves N. Lula
DNDidier B. Nzolo
Didier B. Nzolo
Aline EngoAline Engo
Aline Engo
GTGaston L. Tona
Gaston L. Tona
(1) Background: Malaria heavily affects the Democratic Republic of the Congo (DRC) despite the use of effective drugs. Poor adherence to malaria treatment may contribute to this problem. (2) Methods: In one rural and one urban health area in each of the 11 former provinces of the DRC, all households with a case of malaria in the 15 days preceding the survey were selected and the patients or caregivers were interviewed. Adherence to malaria treatment was assessed by self-declaration about its completion. Logistic regression was used to assess predictors. (3) Results: 1732 households participated. Quinine was the most used drug; adherence to artesunate–amodiaquine was the lowest and the main reason for treatment discontinuation was adverse reactions. Predictors of adherence were residence in an urban area, university education, catholic religion, and adoption of recommended behaviour towards a malaria case. Adherence was significantly lower for responders who obtained information on antimalarials from Community Health Workers (CHW). (4) Conclusions: Usage of recommended drugs and adherence to malaria treatment need to be promoted, especially in rural areas, and CHW involvement needs to be improved. Awareness messages need to be made accessible and comprehensible to poorly educated populations and churches need to be involved.

29 July 2023 in Journal of Electronics, Electromedical Engineering, and Medical Informatics
Verified
Journal Article
Open access
PDF file
LOLeader Lawanga Ontshick
Leader Lawanga Ontshick
JSJean-Christophe Mulangu Sabue
Jean-Christophe Mulangu Sabue
PKPlacide Mbala Kiangebeni
Placide Mbala Kiangebeni
OMOlivier Tshiani Mbayi
Olivier Tshiani Mbayi
NNNsengi Yumva Ntamabyaliro
Nsengi Yumva Ntamabyaliro
RMRostin Mabela Makengo Matendo
Rostin Mabela Makengo Matendo
Our study aimed to identify risk factors associated with mortality in Ebola patients using binary logistic regression analysis and linear discriminant analysis, and to assess the predictive power of these two methods. Our study was a randomized, double-blind, controlled (observational) clinical trial conducted in 2018 during the 10th Ebola outbreak in eastern DRC. The study included 363 patients divided into two treatment arms, including 182 patients treated with MAB114 (Ebang) and 181 patients treated with REGENERON (REGN-EB3 ). After a thorough analysis of the data, both statistical analysis methods selected the same set of variables (risk factors) for the binary logistic regression we obtained: viral load 0.58 (0.5-0.67), creatinine 1.98 (1.58-0.67) and aspartate aminotransferase 0.99 (0.9-1); as for the linear discriminant analysis we have viral load (0.88), creatinine (0.94) and aspartate aminotransferase (0.78). We also see almost the same results when different prediction probabilities are evaluated. Logistic regression predicted a mortality rate of 36.5% and linear discriminant analysis predicted a mortality rate of 38.8%. Using the AUC (area under the curve) score, we were able to evaluate two methods and obtain a score of 0.935 for the binary logistic regression and 0.932 for the linear discriminant analysis. According to the evaluation hypothesis, both methods give the same risk factors (viral load (Ctnp), creatinine and alanine aminotransferase (ALT)) with a probability of 93%.